Royalty Pharma plc and Minerva Neurosciences Inc. announced that Royalty Pharma will acquire Minerva’s royalty interest in seltorexant for an upfront payment of $60 million and up to $95 million in additional milestone payments. The additional payments to Minerva will be contingent on the achievement of certain clinical, regulatory and commercialization milestones. Minerva Neurosciences is entitled to a mid-single digit royalty on worldwide net sales of seltorexant.